Abstract

In this article, Huang et al introduce a comprehensive list of models for extrapolating overall survival data and illustrate their application to a clinical trial data set. They also compare and contrast the model outcomes and provide insights on the tradeoffs in model selection in the context of the probable underlying biomedical processes for immuno-oncology treatments.